Harvard Bioscience (HBIO) Return on Sales (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• On a quarterly basis, Return on Sales rose 2.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.0%, a 1.0% increase from a year earlier, with the FY2025 full-year figure at 0.01%, down 1.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for HBIO reached as high as 0.0% in Q2 2022 and fell as low as 0.02% in Q1 2025.
• Historically, Return on Sales has averaged 0.0% across 5 years, with a median of 0.0% in 2025.
• Across the five-year window, Return on Sales slipped 2 bps in 2025 and grew 2 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.0% in 2022, then surged by 72 bps to 0.0% in 2023, then soared by 189 bps to 0.0% in 2024, then sank by 910 bps to 0.0% in 2025, then slumped by 39 bps to 0.0% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.